Development of curcumin as an epigenetic agent

Area of Science:

• Oncology
• Epigenetics
• Pharmacology

Background:

• Curcumin exhibits broad biological activities, including in cancer treatment.
• Its clinical efficacy is observed despite low plasma concentrations in humans compared to in vitro studies.
• Curcumin's mechanisms involve direct protein interactions and epigenetic modulation of gene expression.

Purpose of the Study:

• To review the novel epigenetic mechanisms of curcumin.
• To explore curcumin's interaction with key epigenetic regulators.
• To highlight curcumin's potential as an epigenetic agent in cancer therapy.

Main Methods:

• Review of existing preclinical and clinical data on curcumin's biological activities.
• Analysis of curcumin's interaction with histone deacetylases (HDACs), histone acetyltransferases (HATs), DNA methyltransferase I (DNMT1), and microRNAs (miRNAs).
• Examination of time- and concentration-dependent gene expression modulation by curcumin in cancer cells.

Main Results:

• Curcumin modulates gene expression through epigenetic mechanisms, including interactions with HDACs, HATs, DNMT1, and miRNAs.
• These epigenetic effects occur in a time- and concentration-dependent manner.
• Curcumin functions as an epigenetic agent, modulating biological processes at low concentrations.

Conclusions:

• Curcumin acts as a potent epigenetic agent with diverse mechanisms.
• Its ability to modulate gene expression epigenetically supports its role in cancer treatment.
• Further preclinical and clinical studies are recommended to investigate curcumin's efficacy as a standalone or combination therapy.